Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT03054142
Recruiting Observational

China Collaborative Study on Epidemiology of Acute Kidney Injury

NCT03054142 · tracked via the Priya Life Science China tracker
Sponsor
XinLing Liang
Phase
Observational
Started
2017-01
Last updated
2022-12-13

Condition(s) studied

Acute Kidney Injury

Investigational drug(s) / intervention(s)

no intervention

Study summary

Acute kidney injury (AKI) is a common clinical syndrome, especially patients in the hospital. AKI has become a huge medical burden in China. Little information is available about this disease burden in our country. The investigators aimed to evaluate the burden of AKI and to analyze the related risk factors.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * The patients diagnosed on the basis of changes in serum creatinine according to the criteria of 2012 Kidney Disease Improving Global Outcomes(KDIGO) Exclusion Criteria: * Serum creatinine record less than two times during hospitalization * Patients being diagnosed with End-stage kidney disease (chronic kidney disease stage 5) * Nephrectomy * Kidney transplantation * Peak serum creatinine of less than 53µ mol/L * Serum creatinine decrease after amputation

Primary outcome measure(s)

  • Incidence of AKI — Jan. 2011 to Oct. 2016

Trial sites (1)

FacilityCityRegionStatus
Nephrology Dept,Guangdong General Hospital Guangzhou Guangdong Recruiting

Other trials for the same condition

Acute Kidney Injury in Critically Ill Patients Enrolling by invitation
Clinical Study to Evaluate the Efficacy and Safety of Mesenchymal Stromal Cells (Amimestrocel ) in Patients With Acute Kidney Injury Recruiting
Phosphate-Containing Replacement Fluid for Patients Undergoing CRRT Starting soon
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+ Recruiting
Novel Biomarkers and Postoperative Kidney Injury in Radical Nephrectomy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03054142 on ClinicalTrials.gov ↗ ← All trials in China